Dr. Mike Reed Joins Rosa & Co. Executive Management Team

Rosa & Co today announced that Michael Reed, Ph.D., has joined Rosa as Vice President. Dr. Reed brings deep clinical pharmacology and drug development expertise in addition to nearly 10 years of experience applying mathematical models of biologic/physiologic systems to product development issues faced by biotechnology, pharmaceutical, and consumer product companies. Before joining Rosa, Dr. Reed headed metabolic disease research at Entelos, Inc., where he supervised multiple research collaborations with major bio-pharmaceutical customers and led the development of complex mathematical models of metabolic disease. Prior to that, Mike held positions of increasing responsibility in preclinical pharmacology and drug development at Shaman Pharmaceuticals and Tularik. Dr. Reed holds a B.S. degree in Biology from the University of Texas at Austin and a Ph.D. in Exercise Physiology from Ohio State University. Following his Ph.D., he completed a post-doctoral fellowship with Gerald Reaven at Stanford University.

"Adding Dr. Reed to our management team continues to extend our top-class scientific capabilities. Mike’s clinical pharmacology and drug development expertise combined with his significant physiologic modeling background will further enhance the relevance of our offerings to our bio-pharmaceutical clients worldwide," said Dr. Ron Beaver, PhD, Rosa’s Cofounder, Chairman, and CEO.

“I’m excited to be joining the team at Rosa,” Mike added. “The application of mathematical modeling to bio-pharmaceutical development is the way forward in a field fraught with challenges. Having worked at the bench and personally faced the critical challenges of time, money, and complexity, I feel that Rosa’s approach offers a unique strategic advantage.”

Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.

Rosa & Co. LLC
751 Laurel St., Ste. 127,
San Carlos, CA 94070

This release was published on openPR.